Pharma News

A new study has revealed that a commonly prescribed anti-depressant, sertraline, marketed  as Zoloft, significantly increased the volume of one brain region in depressed individuals but decreased the volume of two brain areas in non-depressed individuals. The findings of the study also suggest that although it is a common practice to prescribe antidepressants for various disorders besides depression, taking these medicines for treating disorders other than depression may expose us to unknown risks. The study appeared online in Neuropharmacology.

Teva Pharmaceutical Industries Ltd launch Zecuity, the first and only patch system in US designed to provide relief from migraine.  Zecuity is a single-use, disposable patch system that delivers sumatriptan through the skin. Zecuity is a prescription medicine used for the acute treatment of migraine headaches with or without aura in adults.

Sandoz, a Novartis company and a global leader in generic pharmaceuticals launch of first biosimilar Zarxio (filgrastim-sndz). Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA).

Honeywell, a diversified technology and manufacturing leader, introduced Safyr, a high-moisture barrier thermoformable film designed specifically to meet the requirements of India’s domestic pharmaceutical packaging market.

The study findings suggest that falling leptin levels send a hunger signal to the brain's pleasure center to generate the rewarding effects of running. Leptin is a fat cell-derived hormone that signals the brain when the body has enough fuel and energy. The study appeared in Cell Metabolism.

Marijuana may be used to delay rejection of an incompatible organ where transplanted organs may not be a perfect match, says a new research. The findings suggest that THC, the active ingredient in marijuana, might prove to be a useful anti-rejection therapy. The study was published in the Journal of Leukocyte Biology.

A new study reveals Feeling sad can impair our ability to accurately identify colors on the blue-yellow axis. The new research was published in the journal Psychological Science.

Glenmark Pharmaceuticals S.A., GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing. GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation and survival. Glenmark has now completed clinical phase I studies for GBR 830 in the Netherlands.

[adsense:336x280:8701650588]

Scientists have pinpointed a population of neurons in the brain that influences whether one drink leads to two and so on. The discovery could ultimately lead to a cure for alcoholism and other addictions, said researchers from the Texas A and M Health Science Center. They found that alcohol consumption alters the structure and function of neurons in the dorsomedial striatum, a part of the brain known to be important in goal-driven behaviors. The findings were published in the Journal of Neuroscience.